James Blachly

James Blachly, MD

Physician

Make an Appointment

Specialty

Gender

Male

Biography


I’m an oncologist focused on the treatment of patients diagnosed with Hairy Cell, Acute Myeloid, Acute Lymphocytic and Chronic Lymphocytic Leukemia. I’m a member of the Leukemia Research Program at the OSUCCC – James and serve as an assistant professor in Ohio State’s Division of Hematology.

My research interest is in genomics and gene transcription in leukemia and its relevance in experimental therapeutics. My work explores whether and how mutations and transcriptional attributes can be studied in the context of clinical trials to provide prognostic and predictive information relevant to novel anticancer therapies.

I was recently named as one of six recipients of a Young Investigator Award from the National Comprehensive Cancer Network (NCCN) Foundation. I received a six-figure grant for a project titled “Genomic Stratification and Prognostication of Adult Acute Myeloid Leukemia by Combination Mutation Status.”

I love the collaborative spirit at OSUCCC – James, and how we all share the common purpose of providing optimal and effective care and treatment for patients — and the goal of one day living in a world free of cancer.

Education and Background

Education

University of Arkansas College of Medicine

Little Rock, AR

Residencies

University of Arkansas for Medical Sciences Medical Center

Little Rock, AR

Fellowship

Hematology/Oncology

Ohio State University Wexner Medical Center

Columbus, OH

Board Certifications

American Board of Internal Medicine

American Board of Internal Medicine (Subspecialty: Hematology)

American Board of Internal Medicine (Subspecialty: Medicine Oncology)

Academic Department

Department of Internal Medicine

Division of Hematology


Consulting and Related Relationships

At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 12/20/2018, Dr. Blachly has reported relationships with the companies or entities listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office.

AstraZeneca

Gilead Sciences, Inc.

AbbVie Inc.

Publications

Implementation of standardized variant-calling nomenclature in the age of next-generation sequencing: where do we stand?

Eisfeld AK, Blachly JS, Mrózek K, Kohlschmidt J, Walker CJ, de la Chapelle A, Bloomfield CD

Leukemia 33

3/1/2019

Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia.

Mitchell SR, Larkin K, Grieselhuber NR, Lai TH, Cannon M, Orwick S, Sharma P, Asemelash Y, Zhang P, Goettl VM, Beaver L, Mims A, Puduvalli VK, Blachly JS, Lehman A, Harrington B, Henderson S, Breitbach JT, Williams KE, Dong S, Baloglu E, Senapedis W, Kirschner K, Sampath D, Lapalombella R, Byrd JC

Blood Adv 3

2/12/2019

Clinical Trials | Lead

OSU-18296

OSU-17239

OSU-18125

Related Videos

DNA, RNA and Protein
Genes and the Changes That Lead to Cancer
Back to Find a Doctor Search

Make an Appointment

800-293-5066

Please enter a keyword (i.e. Name, Cancer Type) or choose a Principle Investigator

OR

Please enter a keyword (i.e. Name, Location) or choose a Cancer Type

OR